Karyopharm Therapeutics reported $254.09M in Assets for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Acceleron Pharma XLRN:US $ 787.85M 48.2M
Amgen AMGN:US $ 64993M 5220M
Astrazeneca AZN:US $ 107221M 33580M
AstraZeneca AZN:LN 107221M 33580M
Avrobio Inc AVRO:US $ 216.45M 21.64M
Biocryst Pharmaceuticals BCRX:US $ 265.76M 11.52M
Bristol Myers Squibb BMY:US $ 110893M 96M
Eli Lilly And LLY:US $ 48187M 378M
Epizyme EPZM:US $ 332.27M 20.28M
GlaxoSmithKline GSK:LN 78689M 1678M
Karyopharm Therapeutics KPTI:US $ 254.09M 32.47M
Macrogenics MGNX:US $ 392.16M 33.75M
Mirati Therapeutics MRTX:US $ 1253.43M 102.27M
Nektar Therapeutics NKTR:US $ 1277.24M 94.11M
Novartis NOVN:VX SF 121209M 2806M
Novartis NVS:US $ 121209M 2806M
Regeneron Pharmaceuticals REGN:US $ 23671.5M 2185.6M
Sangamo Biosciences SGMO:US $ 772.4M 62.96M
Takeda 4502:JP Y 12560273M 96961M
Tg Therapeutics TGTX:US $ 409.69M 71.71M
Ultragenyx Pharmaceutical RARE:US $ 1484.8M 27.64M
Xencor XNCR:US $ 697.26M 1.66M
YTE INCY:US $ 4198.83M 294.21M